Johnson & Johnson (NYSE: JNJ) reported Q4 EPS of $2.35, $0.11 better than the analyst estimate of $2.24. Revenue for the quarter came in at $23.7 billion versus the consensus estimate of $23.9 billion.

GUIDANCE:

Johnson & Johnson sees FY2023 EPS of $10.50, versus the consensus of $10.33.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.